严重急性呼吸综合征冠状病毒2的联合治疗可降低莫努匹拉韦诱导的致突变性并防止对奈玛特韦/利托那韦耐药突变的选择。
Combined Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 Reduces Molnupiravir-Induced Mutagenicity and Prevents Selection for Nirmatrelvir/Ritonavir Resistance Mutations.
作者信息
Zhou Shuntai, Long Nathan, Rosenke Kyle, Jarvis Michael A, Feldmann Heinz, Swanstrom Ronald
机构信息
Lineberger Comprehensive Cancer Center.
Department of Microbiology and Immunology, University of North Carolina at Chapel Hill.
出版信息
J Infect Dis. 2024 Dec 16;230(6):1380-1383. doi: 10.1093/infdis/jiae213.
Abstract
We investigated the mutation profiles of severe acute respiratory syndrome coronavirus 2 in samples collected from a molnupiravir and nirmatrelvir/ritonavir combination therapy in macaques. We found that molnupiravir induced several nirmatrelvir resistance mutations at low abundance that were not further selected in combination therapy. Coadministration of nirmatrelvir/ritonavir lowered the magnitude of the mutagenetic effect of molnupiravir.
摘要
我们研究了从接受莫努匹拉韦和奈玛特韦/利托那韦联合治疗的猕猴身上采集的样本中严重急性呼吸综合征冠状病毒2的突变谱。我们发现，莫努匹拉韦诱导了几种低丰度的奈玛特韦耐药突变，这些突变在联合治疗中未被进一步选择。奈玛特韦/利托那韦的联合给药降低了莫努匹拉韦的诱变作用强度。
相似文献
1
Combined Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 Reduces Molnupiravir-Induced Mutagenicity and Prevents Selection for Nirmatrelvir/Ritonavir Resistance Mutations.
J Infect Dis. 2024 Dec 16;230(6):1380-1383. doi: 10.1093/infdis/jiae213.
2
Effectiveness of nirmatrelvir/ritonavir and molnupiravir on post-COVID-19 outcomes among outpatients: a target trial emulation investigation.
Emerg Microbes Infect. 2025 Dec;14(1):2469648. doi: 10.1080/22221751.2025.2469648. Epub 2025 Mar 4.
3
Real-world effectiveness and economic analysis of nirmatrelvir/ritonavir, remdesivir, and molnupiravir for treatment of COVID-19 among ambulatory patients in Thailand.
J Infect Public Health. 2025 Aug;18(8):102826. doi: 10.1016/j.jiph.2025.102826. Epub 2025 May 13.
4
Early use of oral antiviral drugs and the risk of post COVID-19 syndrome: A systematic review and network meta-analysis.
J Infect. 2024 Aug;89(2):106190. doi: 10.1016/j.jinf.2024.106190. Epub 2024 Jun 2.
5
The effect of molnupiravir and nirmatrelvir on SARS-CoV-2 genome diversity in severe models of COVID-19.
Microbiol Spectr. 2025 May 6;13(5):e0182924. doi: 10.1128/spectrum.01829-24. Epub 2025 Mar 25.
6
Real-world effectiveness of nirmatrelvir-ritonavir and molnupiravir in non-hospitalized adults with COVID-19: a population-based, retrospective cohort study.
Clin Microbiol Infect. 2025 Mar;31(3):451-458. doi: 10.1016/j.cmi.2024.10.026. Epub 2024 Nov 4.
7
Oral Nirmatrelvir-Ritonavir as Postexposure Prophylaxis for Covid-19.
N Engl J Med. 2024 Jul 18;391(3):224-234. doi: 10.1056/NEJMoa2309002.
8
Antiviral pills could change pandemic's course.
Science. 2021 Nov 12;374(6569):799-800. doi: 10.1126/science.acx9605. Epub 2021 Nov 11.
9
Comparing the effectiveness of molnupiravir and nirmatrelvir-ritonavir in non-hospitalized and hospitalized COVID-19 patients with type 2 diabetes: A target trial emulation study.
Diabetes Obes Metab. 2024 Oct;26(10):4653-4664. doi: 10.1111/dom.15830. Epub 2024 Aug 7.
10
[Molnupiravir or nirmatrelvir-ritonavir reduce the likelihood of hospitalization and mortality in immunocompromised patients with Covid-19.].
Recenti Prog Med. 2024 Sep;115(9):399. doi: 10.1701/4334.43179.
引用本文的文献
1
Combinations of approved oral nucleoside analogues confer potent suppression of alphaviruses and .
bioRxiv. 2025 Mar 11:2025.01.24.633564. doi: 10.1101/2025.01.24.633564.
2
Molnupiravir clinical trial simulation suggests that polymerase chain reaction underestimates antiviral potency against SARS-CoV-2.
medRxiv. 2025 Jan 6:2024.11.21.24317726. doi: 10.1101/2024.11.21.24317726.
3
Molnupiravir in Combination With Nirmatrelvir/Ritonavir: No Cause for Alarm.
J Infect Dis. 2024 Dec 16;230(6):1297-1298. doi: 10.1093/infdis/jiae214.
本文引用的文献
1
Review: The Landscape of Antiviral Therapy for COVID-19 in the Era of Widespread Population Immunity and Omicron-Lineage Viruses.
Clin Infect Dis. 2024 Apr 10;78(4):908-917. doi: 10.1093/cid/ciad685.
2
A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes.
Nature. 2023 Nov;623(7987):594-600. doi: 10.1038/s41586-023-06649-6. Epub 2023 Sep 25.
3
Combined molnupiravir-nirmatrelvir treatment improves the inhibitory effect on SARS-CoV-2 in macaques.
JCI Insight. 2023 Feb 22;8(4):e166485. doi: 10.1172/jci.insight.166485.
4
Unique Molecular Identifiers and Multiplexing Amplicons Maximize the Utility of Deep Sequencing To Critically Assess Population Diversity in RNA Viruses.
ACS Infect Dis. 2022 Dec 9;8(12):2505-2514. doi: 10.1021/acsinfecdis.2c00319. Epub 2022 Nov 3.
5
Lethal mutagenesis as an antiviral strategy.
Science. 2022 Feb 4;375(6580):497-498. doi: 10.1126/science.abn0048. Epub 2022 Feb 3.
6
A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus.
Sci Transl Med. 2022 Jan 19;14(628):eabl7430. doi: 10.1126/scitranslmed.abl7430.
7
β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells.
J Infect Dis. 2021 Aug 2;224(3):415-419. doi: 10.1093/infdis/jiab247.
8
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.
Sci Transl Med. 2020 Apr 29;12(541). doi: 10.1126/scitranslmed.abb5883. Epub 2020 Apr 6.
9
Small-Molecule Antiviral β-d--Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance.
J Virol. 2019 Nov 26;93(24). doi: 10.1128/JVI.01348-19. Print 2019 Dec 15.
10
Primer ID Validates Template Sampling Depth and Greatly Reduces the Error Rate of Next-Generation Sequencing of HIV-1 Genomic RNA Populations.
J Virol. 2015 Aug;89(16):8540-55. doi: 10.1128/JVI.00522-15. Epub 2015 Jun 3.
Zotero 插件